Adjuvant Rosa Damascena has a Small Effect on SSRI-induced Sexual Dysfunction in Female Patients Suffering from MDD

Abstract

Background: Treating major depressive disorders (MDD) with selective serotonin-reuptake inhibitors (SSRIs) may impact negatively on sexual function. On the other hand, a satisfying sexual life is associated with overall life satisfaction. Therefore, managing this negative side effect of SSRIs may have an important role in the treatment of MDD. In a former study, adjuvant Rosa damascena oil improved sexual dysfunction in male patients suffering from both MDD and SSRI-induced sexual dysfunction (SSRI-I SD). The aim of the present study was to test whether the same pattern of results would be observed among female patients suffering from both SSRI-I SD and MDD.

Method: In a double-blind, randomized and placebo-controlled clinical trial, a total of 50 female patients (mean age: 34 years) treated with an SSRI and suffering from MDD and SSRI-I SD were randomly assigned either to the verum (Rosa damascena oil) or to the placebo condition. Patients completed self-ratings of depression and sexual function at baseline, 4 weeks later, and at the end of the study 8 weeks after its start.

Results: Sexual desire, sexual orgasms, and sexual satisfaction increased over time. Patients in the verum group reported decreased pain. Overall sexual score increased in the verum as compared to the placebo condition.

Conclusions: Whereas in male patients suffering from both MDD and SSRI-I SD adjuvant Rosa damascena oil improved sexual function, data on female patients are less robust and suggest only modest effects on female sexual function.

Key words

major depressive disorder (MDD) - female patients - rosa damascena oil - sexual dysfunction - serotonin-reuptake inhibitors (SSRIs) - SSRI-induced sexual dysfunction

• References

• 1 Lopez AD, Mathers CD, Ezzati M et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-1757
• 2 Johannes CB, Clayton AH, Odom DM et al. Distressing sexual problems in United States women revisited: prevalence after accounting for depression. J Clin Psychiatry 2009; 70: 1698-1706
• 3 Bonierbale M, Lançon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Medl Res Opin 2003; 19: 114-124
• 4 Angst J. Sexual problems in healthy and depressed persons. Int Clin Psychopharmacol 1998; 13 (Suppl. 06) S1-S4
• 5 Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 2009; 29: 157-164
• 6 Clayton AH, El Haddad S, Iluonakhamhe JP et al. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opin Drug Saf 2014; 13: 1361-1374
• 7 Grawe K. Neuropsychotherapy. Neuropsychotherapie. Göttingen: Hogrefe; 2004
• 8 Kanfer FH, Reinecker H, Schmelzer D. Self-management therapy: a textbook for clinical practice. Selbstmanagement-Therapie: Ein Lehrbuch für die klinische Praxis. 5^th ed. New York: Springer; 2012
• 9 Mota-Pereira J, Silverio J, Carvalho S et al. Moderate exercise improves depression parameters in treatment-resistant patients with major depressive disorder. J Psychiatr Res 2011; 45: 1005-1011
• 10 Cooney GM, Dwan K, Greig CA et al. Exercise for depression. Cochrane Database Syst Rev 2013; 9: CD004366
• 11 Mura G, Moro MF, Patten SB et al. Exercise as an add-on strategy for the treatment of major depressive disorder: a systematic review. CNS Spectr 2014; 19: 496-508
• 12 Stanton R, Happell B, Haymann M et al. Exercise interventions for the treatment of affective disorders – research to practice. Front Psychiatry 2014; 5: 46
• 13 Haghighi M, Salehi I, Erfani P et al. Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only. J Psychiatr Res 2013; 47: 908-915
• 14 Kellner CH, Greenberg RM, Murrough JW et al. ECT in treatment-resistant depression. Am J Psychiatry 2012; 169: 1238-1244
• 15 Bauer M, Pfennig A, Severus E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 2013; 14: 334-385
• 16 Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians?. World Psychiatry 2010; 9: 155-161
• 17 Reichenpfader U, Gartlehner G, Morgan LC et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf 2014; 37: 19-31
• 18 Graf H, Walter M, Metzger CD et al. Antidepressant-related sexual dysfunction – perspectives from neuroimaging. Pharmacol Biochem Behav 2014; 121: 138-145
• 19 Clark MS, Jansen K, Bresnahan M. Clinical inquiry: How do antidepressants affect sexual function?. J Fam Pract 2013; 62: 660-661
• 20 Clayton AH, El Haddad S, Iluonakhamhe JP et al. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opin Drug Saf 2014; 13: 1361-1374
• 21 Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19: 67-85
• 22 Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009; 29: 259-266
• 23 Garlehner G, Hansen R, Thieda P et al. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: Comparative Effectiveness Review Number 7. Rockville: Agency for Healthcare Research and Quality; 2007. Available at: www.effectivehealthcare.ahrq.gov/ehc/products/7/59/Antidepressants_Final_Report.pdf Accessed: March 5, 2012
• 24 Clayton AH, Zajecka J, Ferguson JM et al. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol 2003; 18: 151-156
• 25 Kanaly KA, Berman JR. Sexual side effects of SSRI medications: potential treatment strategies for SSRI-induced female sexual dysfunction. Curr Womens Health Rep 2002; 2: 409-416
• 26 Keltner NL, McAfee KM, Taylor CL. Mechanisms and treatments of SSRI-induced sexual dysfunction. Persp Psychiatr Care 2002; 38: 111-116
• 27 Montejo AL, Llorca G, Izquierdo JA et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 2001; 62: 10-21
• 28 Balon R. SSRI-Associated Sexual Dysfunction. Am J Psychiatry 2006; 163: 1504-1509
• 29 Bull SA, Hunkeler EM, Lee JY. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 2002; 36: 578-584
• 30 Hu XH, Bull SA, Hunkeler EM et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report vs. physician estimate. J Clin Psychiatry 2004; 65: 959-965
• 31 Maund E, Tendal B, Hróbjartsson A et al. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. BMJ 2014; 348: g3510
• 32 Nurnberg HG. An evidence-based review updating the various treatment and management approaches to serotonin reuptake inhibitor-associated sexual dysfunction. Drugs Today (Barc) 2008; 44: 147-168
• 33 Buss D. Evolutionary Psychology: The New Science of Mind. Essex: Pearson; 2013
• 34 Miller G. The Mating Mind: How Sexual Choice Shaped the Evolution of Human Nature. New York: Random House; 2000
• 35 Damis M, Patel Y, Simpson GM. Sildenafil in the treatment of SSRI-induced sexual dysfunction: a pilot study. Prim Care Companion J Clin Psychiatry 1999; 1: 184-187
• 36 Taylor MJ, Rudkin L, Bullemor-Day P et al. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev 2013; 5: CD003382
• 37 Dolberg OT, Klag E, Gross Y et al. Relief of serotonin selective reuptake inhibitor induced sexual dysfunction with low-dose mianserin in patients with traumatic brain injury. Psychopharmacology 2002; 161: 404-407
• 38 DeBattista C, Solvason B, Poirier J et al. A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J Clin Psychiatry 2005; 66: 844-848
• 39 Segraves RT, Balon R. Sexual Pharmacology: Fast Facts. New York: WW Norton and Company; 2003
• 40 Farnia V, Shirzadifar M, Shakeri J et al. Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial. Neuropsychiatric Disease and Treatment 2015; 11: 625-635
• 41 Boskabady MH, Shafei MN, Saberi Z et al. Pharmacological effects of rosa damascena. Iran J Basic Med Sci 2011; 14: 295-307
• 42 Chevallier A. The Encyclopedia of Medicinal Plants. London: Dorling Kindersely; 1996
• 43 Rusanov K, Kovacheva N, Vosman B et al. Microsatellite analysis of Rosa damascena Mill. accessions reveals genetic similarity between genotypes used for rose oil production and old Damask rose varieties. Theor Appl Genet 2005; 111: 804-809
• 44 Tabaei-Aghdaei SR, Babaei A, Khosh-Khui M et al. Morphological and oil content variations amongst Damask rose (Rosa damascena Mill.) landraces from different regions of Iran. Sci Hortic 2007; 113: 44-48
• 45 Basim E, Basim H. Antibacterial activity of Rosa damascena essential oil. Fitoterapia 2003; 74: 394-396
• 46 Shokouhinejad N, Emaneini M, Aligholi M et al. Antimicrobial effect of Rosa damascena oil on selected endodontic pathogens. Journal of the California Dental Association 2010; 38: 123-126
• 47 Awale S, Tohda C, Tezuka Y et al. Protective effects of rosa damascena and its active constituent on Aß(25–35)-induced neuritic atrophy. Evid Based Complement Alternat Med 2011; 149: 131042
• 48 Ramezani R, Moghimi A, Rakhshandeh H et al. The effect of Rosa damascena essential oil on the amygdala electrical kindling seizures in rat. Pak J Biol Sci 2008; 11: 746-751
• 49 Loghmani-Khouzani H, Sabzi Fini O, Safari J. Essential oil composition of Rosa damascena mill cultivated in central Iran. Scientia Iranica 2007; 14: 316-319
• 50 Kumar N, Bhandari P, Singh B et al. Reversed phase-HPLC for rapid determination of polyphenols in flowers of rose species. J Sep Sci 2008; 31: 262-267
• 51 Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (Suppl. 20) 22-33
• 52 American Psychiatric Association . The Diagnostic and Statistical Manual of Mental Disorders. 5^th ed. Arlington: American Psychiatric Publishing; 2013
• 53 Beck AT. Beck depression inventory. Philadelphia: Center for Cognitive Therapy; 1961
• 54 Fakhri A, Pakpour AH, Burri A et al. The Female Sexual Function Index: translation and validation of an Iranian version. J Sex Med 2012; 9: 514-523
• 55 Kashani L, Raisi F, Saroukhani S et al. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Hum Psychopharmacol 2013; 28: 54-60
• 56 Akhtari E, Raisi F, Keshavarzi M et al. Tribulus terrestris for treatment of sexual dysfunction in women: randomized double-blind placebo-controlled study. Daru 2014; 22: 40
• 57 Katz M, DeRogatis LR, Ackerman R et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med 2013; 10: 1807-1815
• 58 Belkin ZR, Krapf JM, Goldstein AT. Drugs in early clinical development for the treatment of female sexual dysfunction. Expert Opin Investig Drugs 2014; 6: 1-9
• 59 Xu SL, Zhu KY, Bi CW et al. Flavonoids induce the expression of synaptic proteins, synaptotagmin, and postsynaptic density protein-95 in cultured rat cortical neuron. Planta Med 2013; 79: 1710-1714
• 60 Chakraborty J, Singh R, Dutta D et al. Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington’s disease. CNS Neurosci Ther 2014; 20: 10-19
• 61 Merzoug S, Toumi ML, Tahraoui A. Quercetin mitigates Adriamycin-induced anxiety- and depression-like behaviors, immune dysfunction, and brain oxidative stress in rats. Naunyn Schmiedebergs Arch Pharmacol 2014; 387: 921-933
• 62 Hou Y, Aboukhatwa MA, Lei DL et al. Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. Neuropharmacology 2010; 58: 911-920
• 63 Haghighi M, Khodakarami S, Jahangard L et al. In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder. J Psychiatr Res 2014; 58: 109-114